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Abstract
Background: The global pandemic of obesity and the metabolic syndrome are leading causes of mortality and
morbidity. Bariatric surgery leads to sustained weight loss and improves obesity-associated morbidity including remission
of type 2 diabetes. MicroRNAs are small, endogenous RNAs that regulate gene expression post-transcriptionally,
controlling most of the human transcriptome and contributing to the regulation of systemic metabolism. This preliminary,
longitudinal, repeat sampling study, in which subjects acted as their own control, aimed to assess the temporal effect of
bariatric surgery on circulating microRNA expression profiles.
Methods: We used Exiqon’s optimized circulating microRNA panel (comprising 179 validated miRNAs) and miRCURY
locked nucleic acid plasma/serum Polymerase Chain Reaction (PCR) to assess circulating microRNA expression. The
microRNAome was determined for Roux-en-Y gastric bypass (RYGB) patients examined preoperatively and at 1 month,
3 months, 6 months, 9 months and 12 months postoperatively. Data was analysed using multivariate and univariate
statistics.
Results: Compared to the preoperative circulating microRNA expression profile, RYGB altered the circulating
microRNAome in a time dependent manner and the expression of 48 circulating microRNAs were significantly different.
Importantly, these latter microRNAs are associated with pathways involved in regulation and rescue from metabolic
dysfunction and correlated with BMI, the percentage of excess weight loss and fasting blood glucose levels.
Conclusions: The results of this pilot study show that RYGB fundamentally alters microRNA expression in circulation with
a time-dependent progressive departure in profile from the preoperative baseline and indicate that microRNAs are
potentially novel biomarkers for the benefits of bariatric surgery.
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Introduction
Bariatric surgery has been established as the most effective
strategy for inducing sustained weight loss and enhancing
metabolism to manage morbid obesity and its systemic
co-morbidities. These procedures improve longevity and
quality of life and lead to remission of type 2 diabetes melli-
tus (T2DM) and reduction in cardiovascular risk, often in-
dependent of weight loss [1]. The physiological effects of
bariatric surgery include the BRAVE steps (bile flow alter-
ation, reduction of gastric size, anatomical gut rearrange-
ment and altered flow of nutrients, vagal manipulation and
enteric gut hormone modulation) with the associated
modulation of the gut microbiome and a multitude of
downstream physiological and disease-modifying ef-
fects [2, 3]. However, the precise mechanism behind
bariatric surgery remain poorly understood.
MicroRNAs are a family of endogenous,
non-coding RNAs that regulate gene expression at
the post-transcriptional level. These small, evolution-
arily conserved RNA transcripts bind to target mes-
senger RNA (mRNA) transcripts leading to mRNA
cleavage or translational repression [4]. This enables
each of the approximately 3000 distinct human
microRNA sequences to fine-tune or silence several
mRNA targets involved in a diverse array of cellular
pathways. Thus, microRNAs form a complex net-
work of gene ‘super-regulators’ controlling virtually
every biological process. As such microRNAs have
been implicated in the progression of obesity and its
many co-morbidities. MicroRNAs regulate adipogen-
esis, insulin secretion, glucose uptake and lipid me-
tabolism and many other biological processes linked
with obesity [5].
While microRNAs act at the subcellular level, they are
also found in the circulation within exosomes or com-
plexed with high-density lipoproteins or argonaute pro-
teins [6]. The mechanisms whereby microRNAs appear in
the circulation and the biological implications of circula-
tion expression are not understood. However, microRNAs
are stable in circulation, not readily digested by ribonucle-
ases and able to withstand repeated freeze-thaw cycles
allowing for long-term storage of circulatory fluids with-
out compromising the microRNA integrity [7]. They can
also be measured with speed, ease and sensitivity through
quantitative PCR and other platforms. This has given
microRNAs rich clinical and therapeutic potential as novel
biomarkers [8]. Recent studies have reported circulating
microRNAs as biomarkers for cancer, obesity, diabetes
and many other disorders [7, 9, 10].
Recently, single post-surgical timepoint studies have
shown that bariatric surgery modulates circulating micro-
RNA expression [9, 11, 12]. The objective of the present
work was to complete a longitudinal repeat sampling
study in which patients were their own preoperative
controls, to assess the temporal effect of bariatric surgery
on circulating microRNA expression profiles and to iden-
tify potential microRNA biomarkers.
Methods
Recruitment
Plasma samples were collected from 4 men and 5 women
undergoing laparoscopic RYGB at Hull and East Yorkshire
Hospitals NHS Trust in the United Kingdom under ethics
approval 10/H1304/13. All patients were morbidly obese
preoperatively and met qualifying criteria for bariatric sur-
gery set out by NICE [13]. Plasma samples were collected
in a fasting state and body mass index (BMI) and fasting
blood glucose were measured immediately preoperatively
and where possible at 1 month, 3 months, 6 months,
9 months and 12 months postoperatively. All participants
provided informed written consent prior to the study.
Sample preparation and extraction
Plasma samples were acquired by standard venipuncture
and centrifugation in EDTA-coated vacutainer tubes (Bec-
ton Dickinson) and frozen at -80 °C until use. RNA was
extracted from plasma using the mirVana PARIS Isolation
Kit (Life Technologies), according to the manufacturer’s
instructions with one modification; prior to the addition
of acid-phenol:chloroform, 150Amoles of c-elegans miR
39 (Life Technologies) was added as an internal standard
and RNA carrier. RNA was extracted from 100 μl plasma
and eluted in 100 μl nuclease free water. A 4 μl aliquot of
RNA elute was reverse transcribed in 20 μl reactions using
the Universal cDNA Synthesis Kit (Exiqon), according to
the manufacturer’s instructions.
Profiling of circulating microRNA
Plasma samples were profiled using Exiqon’s miRCURY
locked nucleic acid (LNA) platform and Serum/Plasma
Focus microRNA PCR panels, according to the manufac-
turer’s instruction. Panels comprised two 96-well plates
coated with LNA microRNA primers for 179 microRNAs,
selected and optimized by the manufacturer for their typ-
ical expression in circulation [14]. No template and
UniSp3 spike-in primers were included for quality control.
PCR was carried out on the StepOnePlus 7500 PCR sys-
tem (Life Technologies) using the SYBR Green dye as
instructed by the manufacturer.
Data analysis
Pre-processing and initial analysis of profiling data was
performed with Exiqon’s GenEx6 software. The threshold
for expression was set as Cq < 37. MicroRNAs not de-
tected in over 60% of samples were removed from consid-
eration. Individual microRNA expression levels are
expressed relative to preoperative expression. The miR-
Walk (v.2) database of predicted and validated microRNA
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targets and the PANTHER classification system were used
to allocate regulated pathways as previously described
[15]. To ensure confidence and accuracy, only mRNA tar-
gets predicted by 2 or more algorithms were included in
the analysis. Statistical significance was determined by
ANOVA and the Student’s t test with Sidak-Bonferroni
correction for multiple comparisons as appropriate. Ex-
pression of microRNAs was correlated with clinical pa-
rameters by the Pearson test. Principal component
analysis (PCA) pattern recognition was applied to visualise
differences in whole microRNA profiles prior to and fol-
lowing RYGB. All analysis was performed using GraphPad
Prism 6.0 and R (www.r-project.org).
Results
As expected, all patients demonstrated substantial
time-dependent reduction in weight following surgery
(Table 1). Mean BMI decreased gradually and significantly
from 49 kg/m2 to 30.7 kg/m2 and patients lost on average
72% of their mean preoperative excess weight 1 year follow-
ing surgery. Although there were no significant changes in
mean fasting blood glucose following surgery, only 2 out of
the 9 patients in this study were diabetic and both demon-
strated decreases in postoperative fasting blood glucose
relative to their individual preoperative level.
Normalization
Profiling found 159 microRNAs that surpassed de-
tection threshold. This offered multiple normalizing
options to minimize technical variation. Five differ-
ent approaches were assessed; microRNA expression
was (a) not normalized, (b) normalized to the mean
expression of all expressed microRNAs (global
mean), (c) normalized to miR 223-3p and 26a, rela-
tively stable microRNAs as determined by geNorm
[16], (d) normalized to miR 101-3p and 19a, rela-
tively stable microRNAs as determined by Normfin-
der [17] and (e) normalized to a combination of
these 4 endogenous microRNAs. Overall variation
was assessed through coefficient of variances (CV)
and cumulative distribution as previously described
[18] (Additional file 1: Figure S1). The optimum
method was normalization to the combination of
miR 223-3p miR 26a, miR 101-3p and miR 19a
which displayed significantly lower mean CVs of the
50% least variable microRNAs compared to all other
assessed methods (Additional file 1: Figure S1B). As
a result, all profiling data were normalized to these
4 endogenous microRNAs.
Multivariate analysis
Using an untargeted approach, multivariate statistical
analysis with PCA scores plot demonstrated separation
between the preoperative and 5 postoperative groups
(Additional file 2: Figure S2A). There appeared to be
discrete clustering according to time: preoperative profiles
(pink); 1 month postoperative profiles (red); 3 months
postoperative profile (green); 6 month postoperative pro-
files (light blue); 9 month postoperative profiles (blue);
and 12 month postoperative profiles (black). This power-
ful untargeted approach was further demonstrated in the
trajectory PCA, which plots the mean components of all 6
groups (Additional file 2: Figure S2B). The preoperative
and 1 month postoperative microRNA profiles were simi-
lar but there is a notable shift of increasing separation
with each sequential postoperative timepoint. This trajec-
tory shift is also evident in the preoperative-postoperative
comparative heatmap of microRNA expression and the
associated group cluster dendrogram (Additional file 2:
Figure S2C and D).
Univariate analysis
Since each patient served as their own control in this lon-
gitudinal study, we also used univariate analysis in a tar-
getted approach for individual microRNAs. The majority
of circulating microRNAs remained unaltered following
RYGB. However, 48 out of the 159 detected microRNAs
were differentially expressed in at least one postoperative
timepoint compared to preoperative levels (Fig. 1). At
1 month following surgery circulating microRNA levels
were largely unchanged, with only 1 microRNA signifi-
cantly increased and 1 microRNA significantly decreased
Table 1 Summary of patient information and clinical outcomes of surgerya
Patients Pre 1 m 3 m 6 m 9 m 12 m ANOVA
n 9 6 8 7 7 4
Age 46.1 (9.8) – – – – – –
Sex (Female) 5/9 – – – – – –
Diabetics 2/9 – – – – – –
BMI (kg/m2) 49 (10) 41.2 (7.9) 37.5 (6.5) 36.4 (8.2) 33.7 (7.9) 30.7 (4.5) 0.0028 (**)
%EWL 0.0 33.7 (13.5) 48.2 (16.8) 55.9 (18.5) 68.9 (17.5) 71.7 (16.7) 0.0044 (**)
Fasting blood glucose
(mmol/L)
7.5 (5.4) 4.2 (0) 6.9 (3.5) 5.7 (1.4) 5.6 (1.4) 5.9 (1.3) 0.733
aBMI body mass index, EWL excess weight lost. Parentheses indicate standard deviation. **p < 0.001 by ANOVA
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relative to preoperative levels. At 3 months only 1
microRNA was significantly increased and 4 micro-
RNAs were significantly decreased relative to pre-
operative levels. The number of differentiated
microRNAs continued to increase with each sequen-
tial timepoint following RYGB, rising to 10 at
6 months (4 increased, 6 decreased). At 9 months the
expression of 28 microRNAs were significantly altered
(1 increased, 27 decreased) and at 12 months 31
microRNAs were significantly altered (1 increased, 30
decreased) compared to preoperative expression. A
series of volcano plots of circulating microRNA
Fig. 1 Circulating microRNAs significantly deregulated following RYGB. (Top) Circulating microRNAs significantly differentiated at 1 month,
3 months, 6 months, 9 months and 12 months following RYGB. Statistical significance was determined by Student’s t-test with Sidak-Bonferroni
correction for multiple comparisons. (Bottom) A Venn diagram illustrating which significantly differentiated microRNAs are unique and shared
between timepoints following RYGB
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expression at each postoperative timepoint relative to
preoperative levels can be found in Fig. 2.
These changes in circulating microRNA expression fol-
lowing RYGB were broadly characterized into 2 types of
temporal response. The first early response was character-
ized by microRNAs whose expression was significantly
different in the first months following RYGB before
reverting to the preoperative baseline at the later months.
MicroRNAs that followed this pattern included miR
338-3p, miR 93-5p and miR 590, whose levels significantly
decreased in the early months following surgery, as well as
miR 547-3p, miR 27a and mR 33a, whose levels increased
(Fig. 3). However, most microRNAs differentially
expressed following RYGB remained unchanged in the
early months following surgery. Compared to preoperative
levels of expression, their expression significantly altered 6
or 9 months following surgery and this was maintained
and in some cases enhanced at 12 months. These micro-
RNAs comprised the sustained late response. The most
prominent microRNA that followed this pattern was miR
15a, whose expression at 3 months and 6 months
remained comparable to preoperative levels but at
9 months miR 15a levels decreased significantly 6.52 fold
and decreased further to 85 fold at 12 months. Similar
patterns were found with circulating levels of miR 125b,
miR 378a, miR 192, miR 629 and miR 22-5p, all were
Fig. 2 Univariate analysis of profiling data presented in volcano plots. Log fold change against -log p value by Student’s t test of postoperative
microRNA expression at (a) 1 month, (b) 3 months, (c) 6 months, (d) 9 months and (e) 12 months following RYGB relative to preoperative levels.
Each data point represents an individual microRNA that has passed expression threshold. Data points in blue are statistically significant (p < 0.05)
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downregulated following RYGB (Fig. 4). All microRNAs
whose expression was significantly different following
RYGB are listed in Fig. 1 and all detected microRNA ex-
pression data is tabulated in Additional file 3: Table S1.
Correlations with clinical outcomes
Circulating microRNAs levels correlated with clinical
measurements (Additional file 4: Table S2). A total of 16
microRNAs significantly correlated with BMI. Expression
levels of seven microRNAs were positively correlated with
BMI including miR 148a-3p and miR 125b. In contrast
circulating levels of nine microRNAs demonstrated a
negative correlation with BMI including miR 33a. The ex-
pression of 19 circulating microRNAs significantly corre-
lated with the percentage of excess preoperative weight
lost. All but two (miR 301a and miR 374b) correlated
negatively. Nine microRNAs significantly correlated with
fasting blood glucose, including miR 320a and miR
Fig. 3 The early bariatric circulating microRNA response showing temporal selectivity. Normalised logarithmic relative preoperative and
postoperative expression of differentiated microRNAs. a miR 338-3p, (b) miR 574-3p, (c) miR 93-5p, (d) miR 27a, (e) miR 33a, (f) miR 590. Data
represents mean ± standard error of mean. *p < 0.05 by Student’s t test following Sidak-Bonferroni correction for multiple comparisons. Each
patient is represented by a unique symbol
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590-5p. Only one microRNA (miR 346) correlated posi-
tively with fasting blood glucose levels. Additionally, 17
microRNAs significantly correlated with age.
Pathway analysis
To determine the potential biological consequences of
changes in the expression of circulating microRNAs
that made up the early and late post-bariatric re-
sponses, their mRNA targets and associated metabolic
pathways were predicted using miRWalk and
PANTHER bioinformatics (Fig. 5). The regulation of
pathways involved in cell growth and proliferation, in-
flammation and neurological processes were predicted
in both the early and late stages of response. The
early response was also characterized by the predicted
regulation of insulin/IGF pathways and the PI3 kinase
pathway. Predicted pathways unique to the late stage
of response were the cholecystokinin receptor path-
way, α/β-adrenergic receptor pathway, cadherin sig-
naling and the VEGF signaling pathway.
Fig. 4 The late bariatric circulating microRNA response showing progressive temporal selectivity. Normalised logarithmic relative preoperative and
postoperative expression of differentiated microRNAs. a miR 125b, (b) miR 378a, (c) miR 192, (d) miR 629, (e) miR 22-5p and (f) miR 15a. Data
represents mean ± standard error of mean. *p < 0.05, **p < 0.01, ***p < 0.001 by Student’s t test following Sidak-Bonferroni correction for multiple
comparisons. Each patient is represented by a unique symbol
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Discussion
We have shown for the first time that RYGB persistently
and progressively modulates circulating microRNA expres-
sion in a temporal manner with an increasing departure in
profile from the preoperative obese state. In total, RYGB
led to the differentiated expression of 48 circulating micro-
RNAs typified by the selective, time-dependent differential
expression of specific microRNAs. A temporary, immediate
response is followed by a longer-lasting late response.
The circulating microRNAs whose expression is modi-
fied following RYGB are predicted to regulate cell
growth, inflammation and neurological processes, and at
the later months receptor pathways involved in gut hor-
mone signaling, lipolysis and diabetic kidney disease. Al-
though pathway analysis was largely predicted
computationally, many of the circulating microRNAs
whose expression is modified by RYGB have been ex-
perimentally linked with the metabolic syndrome. MiR
93, shown here to be decreased in the first few months
following surgery, inhibits glucose transport and is over-
expressed in insulin-resistant women with polycystic
ovary syndrome [19]. MiR 27, another member of the
Fig. 5 Pathway analysis. a Comparative heatmap of p values of pathways predicted to be regulated by microRNAs in the early and late response
following RYGB. Increasing statistical significance is indicated by the shift in colour from green to red. b The circulating microRNA response
following RYGB and some of the biological processes they’re predicted to regulate. Each line and shade of colour represents a circulating
microRNA in the early and late microRNA responses following RYGB
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early bariatric microRNA response, is a reported pro-
moter of adipogenesis [20]. MiR 15a, decreased an as-
tonishing 85 fold 1 year following surgery, also promotes
adipogenesis [21] and miR 192 has a central regulatory
role in diabetic nephropathy [22]. The altered expression
of these microRNAs following RYGB may explain some
of the mechanisms behind the health benefits associated
with bariatric surgery.
The early postoperative months demonstrated the few-
est changes in circulating microRNA expression, but the
number increased longitudinally. Interestingly, as illus-
trated by the PCA scores plot of circulating microRNA
profiles (Additional file 2: Figure S2), at 1 month follow-
ing RYGB the microRNA circulating profile shifts from
the preoperative profile, before a pronounced and grad-
ual trajectory shift in the opposite direction from
3 months onwards. A possible explanation is that the
initial physiological response to bariatric surgery was
homeostatic as the body attempted to maintain the sta-
tus quo. There is increasing evidence to suggest micro-
RNAs help to maintain system robustness, fine-tuning
or ‘buffering’ gene expression in response to subtle in-
ternal or external stimuli [23]. However, once a tipping
point has been reached this homeostatic safety mechan-
ism was adjusted and reset, moving the individual
physiologically and phenotypically further from the mor-
bidly obese state. In essence, this progressive timeline
shift of circulating microRNA expression reveals a view
of the physiological trajectory of bariatric surgery.
Many of the circulating microRNAs whose expression
has been found to be altered by RYGB in the current
study have also been reported as circulating biomarkers
of T2DM, including of miR 15a, miR 192, miR 130b and
miR 125b [24–26]. The loss of circulating miR 126 in
particular is reportedly a strong selector for T2DM [25].
MiR 126 expression increased over 10 fold in each of the
first 4 postoperative time points relative to preoperative
levels, although none of the increases reached statistical
significance (Additional file 3: Table S1). Importantly, fast-
ing blood glucose levels positivity correlated with circulat-
ing miR 320a (Additional file 3: Table S2), consistent with
previous findings [26] and supporting its candidacy as a
novel diabetic biomarker. Circulating expression of miR
320a also correlated negatively with weight loss. In total,
circulating levels of 9 microRNAs significantly correlated
with fasting blood glucose levels. Correlations between
circulating microRNAs levels and age were also found,
supporting previous studies that show age impacts micro-
RNA levels [27].
Although previous studies [9, 11, 12] have reported
that bariatric surgery leads to changes in the expression
of circulating microRNAs, these were time snapshots
and lacked the temporal dependencies we have uncov-
ered in the present longitudinal study. Lirun et al. looked
at the effect of Roux-en-Y gastric bypass on circulating
microRNAs 3 months postoperatively in diabetic pa-
tients, divided into a low BMI and high BMI preopera-
tive groups [11]. They reported that 39 microRNAs were
differentially expressed after surgery across both groups.
Both Lirun et al. and our study reported the downregu-
lation of let 7, miR 93 and miR 106b expression
3 months postoperatively, while the decrease in miR 16
expression at 3 months in Lirun et al. was only signifi-
cant in our study after 9 months. Interestingly, they re-
ported differences in the postoperative changes in
microRNAs in the low and high BMI groups, suggesting
that changes in microRNAs following surgery may de-
pend on preoperative conditions.
Two further studies assessed circulating microRNA ex-
pression before and 12 months after RYGB. Ortega et al.
[9] reported a significant modulation of 14 circulating
microRNAs including decreases in miR 125b and miR 16
and an increase in miR 221, mirroring our findings (miR
211 increased across all postoperative timepoints, albeit
not significantly). However, they also reported significant
increases in the circulating levels of miR 130b and miR 21.
The expression of both microRNAs were significantly de-
creased in our study 12 months following RYGB. Ortega
et al. were also unable to detect a change in miR 15a fol-
lowing surgery. In another study, Hubal et al. reported the
modified expression of 168 exosome-derived circulating
microRNAs 1 year following RYGB and illustrated a cor-
relation between altered microRNAs and improvements
in insulin resistance [12]. Filtering for microRNAs with
validated targets in insulin signaling or that correlated
with changes insulin resistance, they identified several
surgery-responsive microRNAs, including miR 125b and
miR 122. However, it is important to reiterate that each of
these previous studies measured circulating microRNAs
at a single postoperative timepoint and are therefore
merely snapshots of a dramatically altering physiology.
Our longitudinal study emphasizes that the post-bariatric
surgery circulating microRNAome and associated changes
of physiology are both dynamic.
In rats, circulating levels of miR 122 decrease 60 fold
following RYGB compared to sham-operated animals
[15]. MiR 122 is a liver microRNA responsible for regu-
lating lipid metabolism [28] and its decrease leads to in-
creased glucose transportation, accelerated glycolysis
and the inhibition of gluconeogenesis following RYGB
[15]. This is consistent with the recent discovery that
RYGB reprograms intestinal glucose metabolism by in-
creasing glycolysis and glucose uptake [29], and suggests
miR 122 could contribute to this effect. The present
study also found a consistent decrease in circulating miR
122 in humans following RYGB from 3 months onwards,
although this did not achieve statistical significance
(Additional file 3: Table S1). Other microRNAs that
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decreased following RYGB in rats include miR 93, miR
30e and miR 320 [15] and we report significant de-
creases in the human orthologs of these microRNAs in
our study.
The role of microRNAs following bariatric surgery
remains relatively unexplored and offers potential in-
sights into the dynamic physiological changes that fol-
low surgical intervention. Our study, as with the few
that have preceded it, was limited to a small number
of participating individuals and should be considered
a pilot study at this stage. Additionally, not all sub-
jects provided samples at all post-operative time-
points. Nevertheless, our study confirms the proof of
principle that analysis of circulating microRNAs offers
insight into the dynamic physiological changes associ-
ated with bariatric intervention. Well-designed,
multi-center studies with larger diabetes subsets,
non-bariatric obese and lean control groups and more
robust clinical follow-ups and endpoints would pro-
vide a clearer picture into the role microRNAs play
following bariatric surgery. Although the field is still
in its infancy, bariatric surgery has been consistently
shown to significantly alter circulating microRNA
levels. MicroRNA expression profiles offer a wealth of
biological information and mechanistic insights, as
the changes in the regulation of several core physio-
logical processes are related to the expression of the
microRNAs that regulate them. MicroRNAs can act
as mediators or effectors in positive and negative
feedback loops in wider regulation networks. Their
presence in circulation in exosomes and high-density
lipoprotein or argonaute complexes that can be taken
up in an active form by recipient cells is also suggest-
ive of a potential tissue-to-tissue communicative role
and that microRNAs may have hormonal as well as
biomarker potential [30].
Conclusions
We have shown here that RYGB fundamentally alters
microRNA expression in the circulation in a temporal
manner with an increasing departure from the pre-
operative state. These microRNAs correlate with the
beneficial physiological and metabolic fluxes seen
after these operations and they therefore represent
potentially novel post-surgical biomarkers of surgical
outcomes. There is ongoing debate on updating the
criteria for bariatric surgery, in recognition of its abil-
ity to improve health beyond weight loss. MicroRNA
expression profiles could potentially add another facet
for consideration in the decision-pathway for bariatric
operations and offer additional opportunity for devel-
oping the next generation of combined multi-modal
metabolic interventions to enhance the treatment out-
comes for obesity and its associated disorders.
Additional files
Additional file 1: Figure S1. Normalisation of profiling data. (A)
Coefficient of variance against cumulative distribution for each expressed
microRNA either not normalised (black), normalised to global mean
(blue), miR 223-3p and miR 26a (red), miR 101-3p and miR 19a (purple) or
a combination of miR 223-3p, miR 26a, miR 101-3p and miR 19a (green).
(B) Mean coefficient of variance of the 50% least variable microRNAs for
the four different normalisation methods. Data represent mean ± SEM.
***p < 0.001, ****p < 0.0001 by Student’s t-test. (C) The most stable micro-
RNAs as determined by the geNorm and Normfinder algoritms. M-Value
is the geNorm stability value, defined as the variation of a microRNA
compared to all other microRNAs. SD is the Normfinder stability value,
calculated as the sum of the estimated intragroup and intergroup vari-
ation. (D) Boxplots of raw Cq values of the 4 endogenous microRNAs
used to normalise microRNA expression. (TIF 1470 kb)
Additional file 2: Figure S2. Multivariate analysis of profiling data. (A)
Principal Component Analysis (PCA) scores plot of bariatric circulating
microRNA preoperative (pink), 1 month postoperative (red), 3 month
postoperative (green), 6 month postoperative (light blue), 9 month
postoperative (blue) and 12 month postoperative (black) profiles. (B)
Trajectory PCA scores plot of mean preoperative and postoperative
components ± standard deviation. (C) Comparative heat map of
preoperative and postoperative mean relative microRNA expression and
(D) associated cluster dendrogram. (TIF 2531 kb)
Additional file 3: Table S1. Post-bariatric circulating microRNA fold
changes relative to preoperative levels. (DOCX 48 kb)
Additional file 4: Table S2. Significant Pearson correlations between
circulating microRNA expression and measured clinical parameters.
(DOCX 20 kb)
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